DNA X Inc

DNA X Inc(SONM)股票分析

$2.730

-0.039 (-1.44%)收盤時

Loading chart…
最高
2.970
開盤
2.855
成交量加權均價
2.79
成交量
7.36K
市值
47.89M
最低
2.660
成交金額
20.51K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

DNA X, Inc., formerly Sonim Technologies, Inc., is a digital asset management platform, building on the digital asset trading platform. The Company operates an artificial intelligence (AI) and crypto trading platform designed to automate trading strategies using machine learning technologies. It provides a digital asset trading platform that allows users to trade or swap cryptocurrencies for other cryptocurrencies or cash equivalent currencies. The Company’s DNA X trading website enables users to implement strategies to take advantage of fluctuations in relative values of cryptocurrency pairs. The platform allows users to set up automated trading strategies, monitor other traders’ trading strategies in real time, and simulate trades. The Company generates revenue from trading commissions based on the value of trades executed on its platform. It serves individual investors from around the world and supports its operations through subsidiaries located in China, Germany, and Hong Kong.

AI 分析 of DNA X Inc (SONM)

賣出

Sonim Technologies Inc (SONM) is not a good buy right now due to its significant financial losses and poor performance indicators. The current price is $3.08, and the stock has a 1-year change of -72.92%, indicating a substantial decline in value. Additionally, the RSI is at 30.545, suggesting that the stock is oversold, but this does not guarantee a rebound. The forward P/E ratio is 3.1676, which may seem attractive, but the company has reported negative net income in recent quarters, including a net loss of $4.75 million in Q3 2025. The main risk is the company's ongoing financial instability, as evidenced by a current ratio of 0.76, indicating potential liquidity issues. Overall, the combination of poor financial health and lack of positive catalysts makes SONM a sell at this time.

估值指標

DNA X Inc(SONM)目前預期本益比為 3.17,5 年平均預期本益比為 2.64。

預期本益比

合理
5 年均值 P/E
2.64
目前P/E
3.17
高估
12.23
低估
-6.96

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
0.06
目前EV/EBITDA
0.00
高估
4.11
低估
-3.99

預期股價營收比

低估
5 年均值 P/S
0.22
目前P/S
0.00
高估
0.36
低估
0.09

持有 SONM 的大戶

L

L1 Capital Pty. Limited

+ 持有SONM

-2.98%

3個月報酬率

SONM 常見問題 —— 由 Alphio AI 解答

DNA X, Inc., formerly Sonim Technologies, Inc., is a digital asset management platform, building on the digital asset trading platform. The Company operates an artificial intelligence (AI) and crypto trading platform designed to automate trading strategies using machine learning technologies. It provides a digital asset trading platform that allows users to trade or swap cryptocurrencies for other cryptocurrencies or cash equivalent currencies. The Company’s DNA X trading website enables users to implement strategies to take advantage of fluctuations in relative values of cryptocurrency pairs. The platform allows users to set up automated trading strategies, monitor other traders’ trading strategies in real time, and simulate trades. The Company generates revenue from trading commissions based on the value of trades executed on its platform. It serves individual investors from around the world and supports its operations through subsidiaries located in China, Germany, and Hong Kong. It operates in the Technology sector (TELEPHONE & TELEGRAPH APPARATUS industry).

Sonim Technologies Inc (SONM) is not a good buy right now due to its significant financial losses and poor performance indicators. The current price is $3.08, and the stock has a 1-year change of -72.92%, indicating a substantial decline in value. Additionally, the RSI is at 30.545, suggesting that the stock is oversold, but this does not guarantee a rebound. The forward P/E ratio is 3.1676, which may seem attractive, but the company has reported negative net income in recent quarters, including a net loss of $4.75 million in Q3 2025. The main risk is the company's ongoing financial instability, as evidenced by a current ratio of 0.76, indicating potential liquidity issues. Overall, the combination of poor financial health and lack of positive catalysts makes SONM a sell at this time.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易